Alector (ALEC) Preferred Stock Liabilities (2018)
Alector's (ALEC) quarterly Preferred Stock Liabilities came in at $210.5 million in Q4 2018, little changed quarter-over-quarter from $210.2 million in Q3 2018.
Analysis
Alector (ALEC) Preferred Stock Liabilities (2018) Analysis & Trends
Alector (ALEC) has reported Preferred Stock Liabilities for 1 consecutive years, with $210.5 million the latest figure, recorded in Q4 2018.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $210.5 million in Q4 2018; TTM through Dec 2018 was $210.5 million, a N/A change from a year earlier, with the FY2018 full-year figure at $210.5 million, up 171.69% from the prior year.
- Preferred Stock Liabilities was $210.5 million for Q4 2018 at Alector, roughly flat from $210.2 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $210.5 million in Q4 2018 and troughed at $77.5 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 210.52 Mn |
| Sep 30, 2018 | 210.17 Mn |
| Jun 30, 2018 | 147.57 Mn |
| Mar 31, 2018 | 77.49 Mn |